Premium
CD130 rather than CD126 expression is associated with disease activity in multiple myeloma
Author(s) -
Barillé Sophie,
Thabard Wilfrid,
Robillard Nelly,
Moreau Philippe,
Pineau Danielle,
Harousseau JeanLuc,
Bataille Régis,
Amiot Martine
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01563.x
Subject(s) - flow cytometry , multiple myeloma , interleukin 6 receptor , medicine , interleukin 6 , endocrinology , immunology , cytokine
We analysed the expression of both components of IL‐6R, CD126 the ligand binding protein and CD130 the signal transducing protein, on plasma cells from MGUS and multiple myeloma (MM) cases using flow cytometry. CD126 was detectable in 50% of either MGUS or MM patients without any change of expression during disease progression. In contrast, CD130 expression was up‐regulated during tumoural expansion (43% of MM patients at diagnosis versus 88% at relapse). Finally, combining CD126 and CD130 expression we found a significant increase of the percentage of CD126 + CD130 + patients at relapse, underlying the crucial role of IL‐6 response in the late stage of MM.